Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 1;21(6):576-582.
doi: 10.1097/ACI.0000000000000782.

Nanoparticles in allergen immunotherapy

Affiliations
Review

Nanoparticles in allergen immunotherapy

Alessandra Longo et al. Curr Opin Allergy Clin Immunol. .

Abstract

Purpose of review: Allergen immunotherapy is the only recognized causal treatment for allergic disease that modulates the immune system toward a tolerogenic or desensitized state. Allergens or their derivative preparations are formulated with adjuvants of different origin and having diverse immunological functions, such as prolonged tissue release and specific immunomodulatory properties. In the last 2 decades, thanks to developments in the field of nanotechnology, more biosafe nanoscale materials have become available for use as pharmaceutical adjuvants in medical research.

Recent findings: Nanomaterials possess unique and versatile properties which can be employed to develop drug carriers with safer profiles, better stability in physiological conditions and immunomodulatory properties. Nanoparticles can have an adjuvant effect per se or also when they are packed in structures whose physical-chemical properties can be handled in a way that also influences its release dynamics. In particular, it has been suggested that nanoparticle preparations can be put in complexes or loaded with allergens or allergenic extracts, opening the way to innovative paradigms.

Summary: In this review, we analyze allergen/nanoparticle properties in terms of cytotoxicity, stability and immunogenic reaction in in-vitro and animal systems.

PubMed Disclaimer

References

    1. Noon L. Prophylactic inoculations against hay fever. Lancet 1911; 177:1572–1573.
    1. Komlosi ZI, Kovacs N, Sokolowska M, et al. Highlights of novel vaccination strategies in allergen immunotherapy. Immunol Allergy Clin North Am 2020; 40:15–24.
    1. Schijns V, Fernandez-Tejada A, Barjaktarovic Z, et al. Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. Immunol Rev 2020; 296:169–190.
    1. Nel AE, Madler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009; 8:543–557.
    1. Ding D, Zhu Q. Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular therapeutics. Mater Sci Eng C Mater Biol Appl 2018; 92:1041–1060.